The Role of Autoimmunity and Obesity in Polycystic Ovary Syndrome

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05929950

Enrollment

Registered

2023-07-03

Start date

2023-08-01

Completion date

2024-06-01

Last updated

2023-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome

Keywords

autoimmunity, obesity, Polycystic ovary syndrome

Brief summary

The goal of the study is to detect autoantibodies in the serum of the women with PCOS and evaluate the obesity markers to investigate the the role of autoimmunity and obesity in PCOS

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

12 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* patients diagnosed with PCOS according to the Rotterdam (2003) criteria.

Exclusion criteria

* Patients with other causes of hyperandrogenism as congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome, hyperprolactinemia, virilizing ovarian or adrenal tumors and those taking drugs affecting insulin resistance, such as estrogens, oral contraceptives and corticosteroids during the previous three months before the study.

Design outcomes

Primary

Measure	Time frame	Description
measuring serum anti-ovarian, anti-nuclear, anti-double stranded and anti-thyroid antibodies	3 months after recruitment	Theses markers will be measured using ELISA technique

Countries

Egypt

Contacts

Primary ContactOla AH Hamed, Assistant lecturer

ola.hamed@med.sohag.edu.eg2001061137434

Outcome results